Physician profile
Harrison Smith
NPI 1144909862
$1,924.54
in general payments reported to CMS, 2019-2025
19 companies · $836 in 2025
The $836 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,089 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $483.59 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $410.27 | 2024-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $299.59 | 2024-2025 | |
| Axsome Therapeutics, INC. | $164.35 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $83.28 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $79.14 | 2024-2025 | Veozah |
| Novo Nordisk INC | $66.87 | 2024 | Rybelsus, Ozempic |
| Pfizer INC. | $52.93 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.28 | 2024 | |
| Dexcom, INC. | $37.20 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $30.09 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Exact Sciences Corporation | $29.87 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $28.13 | 2024-2025 | Pediarix, Bexsero, Menveo |
| Phathom Pharmaceuticals, INC. | $24.17 | 2025 | Voquezna |
| Neurocrine Biosciences, INC. | $21.55 | 2024 | Ingrezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $20.39 | 2025 | Fanapt |
| Tris Pharma INC | $19.38 | 2024 | Dyanavel Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.88 | 2025 | Xifaxan |
| Dynavax Technologies Corporation | $11.58 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harrison Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.